Precision BioSciences, Inc.
DTILHealthcare|Biotechnology|US
$10.60
+0.73 (+7.40%)
Tangible Book / Share
$1.85
Cash / Share
$2.98
Clinical Trials (184)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06464510 Norepinephrine and Vasopressin for Rescue Versus Early Vasopressin for Vasopressor Dependent Sepsis | Septic Shock | P3 | Recruiting | 2,800 | RCT, Open-label | Early Vasopressin, Norepinephrine and Vasopressin for Rescue |
| NCT05818553 A Clinical Trial of PRAX-562 in Subjects With Developmental and Epileptic Encephalopathies (DEE) | SCN2A Encephalopathy, SCN8A Encephalopathy | P2P3 | Active | 77 | RCT, Double-blind | PRAX-562 |
| NCT07505004 Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures | Focal Epilepsy | P3 | Active | 300 | RCT, Double-blind | 40 mg/day vormatrogine for 12 weeks, 30 mg/day vormatrogine for 12 weeks, 20 mg/day vormatrogine for 12 weeks, Placebo |
| NCT07010471 A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine | Developmental and Epileptic Encephalopathy 1 | P3 | Active | 160 | RCT, Double-blind | 1.0mg/kg/day PRAX-562, 1.5mg/kg/day PRAX-562, Placebo |
| NCT06087276 Essential 3 - Decentralized, Phase 3 Study Evaluating the Safety and Efficacy of Ulixacaltamide in Essential Tremor (ET) | Essential Tremor | P3 | Recruiting | 1,000 | RCT, Double-blind | 60 mg ulixacaltamide, Placebo |
| NCT07019922 A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety | Epileptic Encephalopathy, SCN2A Encephalopathy | P3 | Recruiting | 40 | Open-label | 1mg elsunersen, 0.5mg elsunersen |
| NCT07429240 PBGENE-DMD Phase 1/2a Safety and Preliminary Efficacy Study in Duchenne Muscular Dystrophy (FUNCTION-DMD) | Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMD | P1P2 | Recruiting | 18 | Open-label | PBGENE-DMD (IV) |
| NCT07693140 Low-Dose Radiotherapy for Alzheimer's Disease | Alzheimer Dementia, Dementia | P1P2 | Recruiting | 50 | Open-label | — |
| NCT04271644 BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease | Multiple Myeloma, Neoplasm, Plasma Cell | P1P2 | Recruiting | 80 | Open-label | BCMA CAR-T cells |
| NCT05334823 A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents | Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL | P2 | Recruiting | 100 | Open-label | pCAR-19B cells |
| NCT04616209 Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients | Non-small Cell Lung Cancer | P1P2 | Recruiting | 24 | Open-label | donor-derived NK cell infusion |
| NCT04781634 a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B-ALL | B-ALL | P1P2 | Recruiting | 40 | Open-label | CD19 and CD22 targeted prime CAR-T cells |
| NCT05737784 A Clinical Trial of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy | SCN2A-DEE, Epilepsy | P1P2 | Active | 60 | RCT, Double-blind | PRAX-222 - Initial Dose, PRAX-222 - Initial Ascending Doses, PRAX-222 - Optional Ascending Doses, PRAX-222 - Fixed Doses |
| NCT04776330 a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease | Multiple Myeloma, Neoplasm, Plasma Cell | P1P2 | Recruiting | 80 | Open-label | BCMA targeted prime CAR-T cells |
| NCT04765137 Evaluate the Effect of Atorvastatin on Cerebrovascular Reactivity in Mild Cognitive Impairment (MCI) | Mild Cognitive Impairment | P2 | Recruiting | 20 | Open-label | Atorvastatin Oral Tablet |
| NCT06908356 An Open Label Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adults With Focal Onset or Tonic-Clonic Seizures | Focal Onset Seizure, Primary Generalized Epilepsy | P2 | Recruiting | 50 | Open-label | 30mg PRAX-628 |
| NCT03476681 Study of NEO-201 in Solid Tumors Expansion Cohorts | Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma | P1P2 | Active | 121 | Open-label | NEO-201 in combination with pembrolizumab |
| NCT06680232 Phase 1 Study to Evaluate Safety and Antiviral Activity of PBGENE-HBV in Adult Patients With Chronic Hepatitis B | HEPATITIS B CHRONIC | P1 | Recruiting | 45 | Open-label | PBGENE-HBV |
| NCT06768151 A Clinical Trial of CEA Targeting CAR-T for CEA Positive Advanced Lung Cancer | Advanced Lung Cancer | P1 | Recruiting | 48 | Open-label | Targeted CEA CAR-T, Targeted CEA CAR-T |
| NCT06690827 Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/Refractory AML or BPDCN | AML (Acute Myeloid Leukemia), BPDCN (Blastic Plasmacytoid Dendritic Cell Neoplasm) | P1 | Recruiting | 30 | Open-label | Anti-CD123 CAR NK cells |
| NCT06126406 Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes（CAR-T） for CEA Positive Advanced Malignant Solid Tumors | Gastric Cancer, Colon Cancer | P1 | Recruiting | 60 | Open-label | CEA-targeted CAR-T cells, CEA-targeted CAR-T cells |
| NCT07247396 CEA CAR-T Therapy After Cytoreduction in Colorectal Cancer Patients With Peritoneal Metastases | Peritoneal Metastases From Colorectal Cancer | P1 | Recruiting | 12 | Open-label | CEA-targeted CAR-T cells |
| NCT07331467 Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE | Systemic Lupus Erythematosus | P1 | Recruiting | 18 | Open-label | CD19 CAR-T cells |
| NCT06180174 Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell Lymphoma | B Cell Lymphoma, Non Hodgkin Lymphoma | P1 | Recruiting | 24 | Open-label | MC-1-50 |
| NCT06992583 Targeted Anti-CEA CAR-T Immunotherapy for Advanced Lung Cancer | Advanced Lung Cancer | P1 | Recruiting | 60 | Open-label | Targeted CEA CAR-T, Targeted CEA CAR-T |
| NCT07403097 Study of CD19 CAR-T Therapy for Refractory SLE | Systemic Lupus Erythematosus | P1 | Recruiting | 18 | Open-label | PTOC1 |
| NCT06892145 Clinical Trial of CD19 Targeted CAR-T Cell in Refractory Adult SLE | Systemic Lupus Erythematosus (SLE), Refractory | P1 | Recruiting | 12 | Open-label | MC-1-50 |
| NCT07239323 In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies | B-Acute Lymphoblastic Leukemia, B Cell Non-Hodgkin's Lymphoma | P1 | Recruiting | 24 | Open-label | Invivo CAR-T |
| NCT06789172 A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors | Solid Tumours, Sarcoma | P1 | Recruiting | 146 | Open-label | OKN4395, H2 Receptor Antagonist |
| NCT06686524 Clinical Study of CD19 Targeted Universal Chimeric Antigen Receptor T Lymphocytes (UCAR-T) for the Treatment of Refractory Juvenile Dermatomyositis (RJDM) | Dermatomyositis, Juvenile, Dermatomyositis | P1 | Recruiting | 18 | Open-label | Anti-CD19 UCAR-T cells |
| NCT07456371 PIC1 Injection Therapy for Relapsed/Refractory B-NHL | Non-Hodgkin Lymphoma | P1 | Recruiting | 18 | Open-label | PIC1 Injection |
| NCT06821048 Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors | Colorectal Cancer, Stomach Cancer | P1 | Recruiting | 18 | Open-label | Intraperitoneal infusion of FAST CEA-targeted CAR-T |
| NCT06043466 A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors | Colorectal Cancer, Esophagus Cancer | P1 | Recruiting | 30 | Open-label | CEA-targeted CAR-T cells |
| NCT07318259 Study of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLE | Systemic Lupus Erythematosus | P1 | Recruiting | 18 | Open-label | BCMA/CD70 CAR-T cells |
| NCT06945523 Clinical Study on Chimeric Antigen Receptor T Lymphocyte (CAR-T) Targeting CEA for the Treatment of CEA - Positive Advanced Lung Cancer | Advanced Lung Cancer | P1 | Recruiting | 60 | Open-label | Targeted CEA CAR-T, Targeted CEA CAR-T |
| NCT05518253 A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors | Metastatic Tumor, Advanced Solid Tumor | P1 | Recruiting | 30 | Open-label | CD70 CAR-T cells, CD70 CAR-T cells |
| NCT06909474 Clinical Trial of CD5-targeted CAR-NK Therapy for Relapse/Refractory T-Cell Hematologic Malignancies | T-ALL/Lymphoma | P1 | Recruiting | 15 | Open-label | Anti-CD5 CAR NK cells |
| NCT07184450 Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic Diseases | Juvenile Dermatomyositis (JDM), Polyarticular Juvenile Idiopathic Arthritis | P1 | Recruiting | 11 | Open-label | BCMA/CD70-targetd CAR-T |
| NCT07346846 A Study of BGM-2121 in Patients With Advanced Solid Tumors | Advanced Solid Tumors | P1 | Recruiting | 35 | Open-label | BGM-2121 |
| NCT06903117 Anti-CEA CAR-T for Advanced CEA-Positive Lung Carcinoma | Advanced Lung Cancer | P1 | Recruiting | 60 | Open-label | Targeted CEA CAR-T, Targeted CEA CAR-T |
| NCT06934447 Study of BCMA/CD70 CAR-T Therapy for Refractory cSLE | CAR T Cell Therapy, Systemic Lupus Erythematosus | P1 | Recruiting | 18 | Open-label | anti-BCMA/CD70-CAR-T cells |
| NCT07715630 In Vivo PICX CAR-T Therapy for R/R Multiple Myeloma | Relapsed or Refractory Multiple Myeloma (RRMM) | P1 | Recruiting | 15 | Open-label | Invivo CAR-T |
| NCT07179692 CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors | Lung Cancer, Gastric Cancer | P1 | Recruiting | 108 | Open-label | CEA-targeted CAR-T cells, CEA-targeted CAR-T cells, CEA-targeted CAR-T cells |
| NCT06569472 Clinical Trial of CD19-targeted CAR-T Therapy for Refractory Juvenile Dermatomyositis | Juvenile Dermatomyositis | P1 | Recruiting | 10 | Open-label | CD19-targetd CAR-T |
| NCT06222853 Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Refractory Systemic Lupus Erythematosus | Systemic Lupus Erythematosus, CAR-T Cell Therapy | P1 | Active | 22 | Open-label | anti-CD19-CAR-T cells |
| NCT07250386 A Study of CEA-Targeted CAR-T Therapy in Patients With CEA-Positive Advanced Solid Tumors | NSCLC (Advanced Non-small Cell Lung Cancer), Breast Cancer | P1 | Recruiting | 48 | Open-label | CEA-targeted CAR-T (Intravenous), CEA-targeted CAR-T (Intrapleural) |
| NCT06215950 A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Gynecologic Cancer | Ovarian Cancer, Cervix Cancer | P1 | Recruiting | 36 | Open-label | CD70 CAR-T cells, CD70 CAR-T cells |
| NCT05121090 Lille Study for Childhood Health Promotion | Overweight, Infant, Overweight and Obesity | Active | 460 | — | — | |
| NCT04499833 HepatoPredict Prognostic Tool for the Decision of Liver Transplant in Hepatocellular Carcinoma | Hepatocellular Carcinoma, Scirrhous, Recurrence Tumor | N/A | Recruiting | 40 | Open-label | — |
| NCT04586075 UW Undiagnosed Genetic Diseases Program | Rare Diseases, Genetic Disease | Recruiting | 1,000 | — | — | |
| NCT06813417 CAR T Therapy With GCAR1 for Relapsed Alveolar Soft Part Sarcoma | Sarcoma, Alveolar Soft Part Sarcoma (ASPS) | Early P1 | Active | 1 | Open-label | GCAR1 |
| NCT07325578 U.S. Prospective Evaluation of EPIONE Device for Percutaneous MSK Procedures | Bone Tumor, Osteoporosis | N/A | Recruiting | 60 | Open-label | — |
| NCT07015801 CMV-specific Donor-derived T Lymphocytes for the Treatment of Recalcitrant CMV Infection in a Patient With Primary Immunodeficiency | Cytomegalovirus Viremia, Cytomegalovirus Pneumonia | N/A | Active | 1 | Open-label | CMV-VST |
| NCT06601166 CONtiNuous glucosE Monitoring (CGM) in People wiTh Type 2 Diabetes Not on Insulin | Type 2 Diabetes | N/A | Active | 283 | RCT, Open-label | — |
| NCT06723275 LEOPARD Prospective Validation Cohort 1 | Decompensated Liver Cirrhosis, Primary Biliary Cholangitis | Recruiting | 630 | — | — | |
| NCT04334031 Deployment o the Multidisciplinary Prospective Cohort Imminent | Chronic Inflammatory Disease, Angioedema | N/A | Recruiting | 2,200 | Open-label | — |
| NCT03957252 Validation of ClarityDX Prostate as a Reflex Test to Refine the Prediction of Clinically-significant Prostate Cancer | Prostate Cancer, Prostate Cancer Screening | Active | 2,800 | — | — | |
| NCT07168993 Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, 6 to <30 mm in Diameter, Determined by LDCT. | Lung Cancer (Diagnosis) | N/A | Recruiting | 2,063 | Open-label | — |
| NCT00944216 Efficacy and Safety of Salkera Emollient Foam in the Treatment of Moderate to Severe Keratosis Pilaris, a Prospective Study | Keratosis Pilaris | P4 | Terminated | 1 | Open-label | Salkera Emollient Foam |
| NCT00782054 Evaluation of Post Burn Rehabilitation Population for Itch Control | Pruritus, Itching | P4 | Completed | 23 | RCT, Double-blind | — |
| NCT04832425 A Clinical Trial of PRAX-114 in Participants With Major Depressive Disorder | Major Depressive Disorder | P2P3 | Completed | 216 | RCT, Double-blind | PRAX-114, Placebo |
| NCT02546102 Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma | Glioblastoma Multiforme | P3 | SUSPENDED | 234 | RCT, Double-blind | ICT-107, Placebo |
| NCT07287163 Clinical Trial of Vormatrigine in Adult Patients With Epilepsy | Epilepsy, Tonic-Clonic, Focal Seizure | P3 | By Invite | 700 | Open-label | vormatrogine |
| NCT04410133 Study to Establish the Diagnostic Performance of 18F Fluciclovine PET in Detecting Recurrent Brain Metastases | Brain Metastases | P3 | Completed | 151 | Open-label | 18F fluciclovine |
| NCT06999902 Double-blind, Randomized Trial of PRAX-628 in Adults With Focal Seizures to Evaluate Efficacy and Safety (POWER1) | Focal Seizure | P2P3 | Completed | 255 | RCT, Double-blind | 20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeks, Placebo |
| NCT04030195 Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL | Non-Hodgkin's Lymphoma, Relapsed, Chronic Lymphoid Leukemia in Relapse | P1P2 | Completed | 18 | Open-label | Fludarabine, Cyclophosphamide |
| NCT04648475 Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma | Leukemia, B-cell, Lymphoma, B-Cell | P1P2 | Unknown | 40 | Open-label | CD19 and CD22 targeted CAR-T cells |
| NCT04272151 Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma | Multiple Myeloma, Multiple Myeloma in Relapse | P1P2 | Unknown | 40 | Open-label | BCMA CAR-T cells |
| NCT04272125 Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid Leukemia | Leukemia, Leukemia, Myeloid | P1P2 | Unknown | 40 | Open-label | CD123 CAR-T cells |
| NCT05414422 A Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety and Efficacy of PCN-101 in TRD | Treatment Resistant Depression | P2 | Completed | 102 | RCT, Double-blind | PCN-101, Placebo |
| NCT01280552 A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM) | Glioblastoma Multiforme | P2 | Completed | 124 | RCT, Double-blind | ICT-107, Placebo DC |
| NCT06006390 CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors | Gastric Cancer, Colon Cancer | P1P2 | Unknown | 60 | Open-label | CEA-targeted CAR-T cells, CEA-targeted CAR-T cells |
| NCT01828177 An Evaluation of PDI-320 in Comparison to Its Monads in Adults With Rosacea | Rosacea | P2 | Unknown | 200 | RCT, Single-blind | PDI-320, PDI-320 Monad #1, PDI-320 Monad #2, Vehicle |
| NCT05549921 Phase II Study of TAEST16001 in Soft Tissue Sarcoma | Soft Tissue Sarcoma | P2 | Terminated | 8 | Open-label | NY-ESO-1(TCR Affinity Enhancing Specific T cell Therapy) |
| NCT01834235 QUILT-3.010: A Study of Gemcitabine and Nab-paclitaxel With or Without NPC-1C to Treat Patients With Pancreatic Cancer | Pancreatic Cancer, Adult | P1P2 | Terminated | 81 | RCT, Open-label | Gemcitabine, nab-paclitaxel, NPC-1C |
| NCT07040436 Assessment of Safety and Efficacy of OPM-101 Combined With Anti-PD-1 in Patients With Advanced Melanoma Showing Resistance to Anti-PD-1 | Advanced Melanoma | P1P2 | Not Yet Recruiting | 41 | Open-label | OPM-101 |
| NCT06006403 Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm | Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | P1P2 | Completed | 5 | Open-label | CD123 targeted CAR-NK cells |
| NCT02963493 A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | Multiple Myeloma | P2 | Completed | 157 | Open-label | Melphalan flufenamide (Melflufen), Dexamethasone |
| NCT04123470 A Phase I/II Trial Investigating LOAd703 in Combination With Atezolizumab in Malignant Melanoma | Malignant Melanoma | P1P2 | Completed | 24 | Open-label | atezolizumab |
| NCT04348643 Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer | Solid Tumor, Lung Cancer | P1P2 | Withdrawn | — | Open-label | CEA CAR-T cells |
| NCT04782193 a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell Lymphoma | B Cell Lymphoma | P1P2 | Unknown | 40 | Open-label | CD19 and CD22 targeted prime CAR- T cells |
| NCT05387642 A Clinical Trial of PRAX-114 in Participants With Essential Tremor | Essential Tremor | P2 | Withdrawn | — | RCT, Double-blind | 10 mg PRAX-114, 20 mg PRAX-114, and Placebo, 10 mg PRAX-114 or 20 mg PRAX-114 |
| NCT07161193 Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases | Autoimmune Diseases | P1P2 | Not Yet Recruiting | 30 | Open-label | CD19 CAR-T cells |
| NCT04649983 CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma | Leukemia, B-cell, Lymphoma, B-Cell | P1P2 | Unknown | 40 | Open-label | CD19 and CD22 targeted CAR-T cells |
| NCT04271800 Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma | Leukemia, Lymphoma | P1P2 | Unknown | 40 | Open-label | CD19 CAR-T cells |
| NCT04410367 Study to Establish Image Interpretation Criteria for 18F Fluciclovine PET in Detecting Recurrent Brain Metastases (PURSUE) | Brain Metastases | P2 | Completed | 23 | Open-label | 18F fluciclovine |
| NCT04265963 CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia | Leukemia, Leukemia, Myeloid | P1P2 | Unknown | 45 | Open-label | CD123 CAR-T cells |
| NCT04271410 CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma | Leukemia, Lymphoma, Large B-Cell, Diffuse | P1P2 | Unknown | 80 | Open-label | CD19 CAR-T cells |
| NCT01826461 An Evaluation of PDI-192 0.1% in Comparison to PDI-192 0.15% in the Treatment of Mild to Moderate Atopic Dermatitis | Atopic Dermatitis | P2 | Completed | 151 | RCT, Double-blind | PDI-192, Vehicle |
| NCT05538195 Safety and Efficacy of CEA-targeted CAR-T for CEA-positive Advanced Malignant Solid Tumors | Gastric Cancer, Colon Cancer | P1P2 | Completed | 17 | Open-label | CEA-targeted CAR-T cells, CEA-targeted CAR-T cells |
| NCT01040000 QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer | Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer | P1P2 | Completed | 94 | Open-label | NPC-1C/NEO-102 |
| NCT05021991 A Clinical Trial of 2 Doses of PRAX-944 in Participants With Essential Tremor | Essential Tremor | P2 | Completed | 133 | RCT, Double-blind | 100 mg PRAX-944, 60 mg PRAX-944, Placebo, Flexibly dosed 20 mg to 100 mg PRAX-944 |
| NCT05260541 A Clinical Trial of PRAX-114 in Participants With Post-Traumatic Stress Disorder | Post-traumatic Stress Disorder, Post Traumatic Stress Disorder | P2 | Terminated | 11 | RCT, Double-blind | 60 mg PRAX-114 or 40 mg PRAX-114, Placebo, 40 mg PRAX-114 |
| NCT04969510 A Clinical Trial of Adjunctive and Monotherapy PRAX-114 in Participants With Major Depressive Disorder | Major Depressive Disorder | P2 | Completed | 110 | RCT, Double-blind | 10 mg PRAX-114, 20 mg PRAX-114, 40 mg PRAX-114, 60 mg PRAX-114, Placebo |
| NCT05021978 A Clinical Trial of PRAX-944 in Participants With Essential Tremor | Essential Tremor | P2 | Completed | 24 | RCT, Double-blind | Part A: 20 and 40 mg PRAX-944, Part B: 120 mg PRAX-944, Part B: 120 mg PRAX-944 and Placebo |
| NCT04649112 Dose-escalation Study of Safety of PBCAR19B in Participants With CD19-expressing Malignancies | CD19 Expressing Malignancies, Hematologic Malignancy | P1 | Completed | 13 | Open-label | — |
| NCT04171843 A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple Myeloma | Relapsed/Refractory Multiple Myeloma | P1 | Terminated | 48 | Open-label | Fludarabine, Cyclophosphamide, Nirogacestat |
| NCT02049489 A Study of ICT-121 Dendritic Cell Vaccine in Recurrent Glioblastoma | Glioblastoma Multiforme | P1 | Completed | 20 | Open-label | ICT-121 DC vaccine |
| NCT04888468 Phase I Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents | Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL | P1 | Completed | 9 | Open-label | pCAR-19B cells |
| NCT06840925 A Clinical Trial to Evaluate the Relative Bioavailability of PRAX-628 | Healthy | P1 | Completed | 16 | RCT, Open-label | PRAX-628 |
| NCT04888442 Phase I Study of pCAR-19B in the Treatment of Adult CD19-positive Relapsed/Refractory B-ALL | Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia | P1 | Unknown | 18 | Open-label | pCAR-19B cells |
| NCT06010875 A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors | Renal Cell Carcinoma, Ovarian Cancer | P1 | Unknown | 48 | Open-label | CD70 CAR-T cells, CD70 CAR-T cells |
| NCT04861480 Dual-target CAR-T Cells (C-4-29) in the Treatment of Relapsed/Refractory Multiple Myeloma | Multiple Myeloma in Relapse, Multiple Myeloma, Refractory | P1 | Unknown | 18 | Open-label | C-4-29 Cells |
| NCT05420545 A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors | Metastatic Tumor, Advanced Solid Tumor | P1 | Unknown | 36 | Open-label | CD70 CAR-T cells, CD70 CAR-T cells |
| NCT05468190 A Clinical Research About CD70-positive Advanced/Metastatic Solid Tumors Treated by CD70-targeted CAR-T | Metastatic Tumor, Advanced Solid Tumor | P1 | Unknown | 48 | Open-label | CD70 CAR-T cells, CD70 CAR-T cells |
| NCT05396300 A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors | Colorectal Cancer, Solid Cancers | P1 | Completed | 58 | Open-label | Intraperitoneal infusion of FAST CEA-targeted CAR-T, CEA CAR-T cells, CEA CAR-T cells |
| NCT03844191 A Randomized Phase 1 Dose-Escalation Study of Subcutaneously(SC) Administered RUC-4 | Coronary Disease | P1 | Completed | 44 | RCT, Double-blind | RUC-4 Compound |
| NCT04252118 Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With COVID-19 | COVID-19 | P1 | Unknown | 20 | Open-label | MSCs |
| NCT04318964 TAEST16001 in the Treatment of Soft Tissue Sarcoma | Soft Tissue Sarcoma | P1 | Unknown | 12 | Open-label | TAEST16001 cells |
| NCT07271446 An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer | Non-small Cell Lung Cancer | P1 | Completed | 8 | Open-label | PB101 plus EGFR-TKI including gefitinib, erlotinib, afatinib, or osimertinib |
| NCT04749433 Study of [11C]CPPC to Assess the Safety and Tolerability in Patients With ALS | Amyotrophic Lateral Sclerosis | P1 | Terminated | 4 | Open-label | [11C]CPPC Injection |
| NCT06641024 Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/ Refractory B-ALL | Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia | P1 | Not Yet Recruiting | 24 | Open-label | MC-1-50 |
| NCT06056921 Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease | SLE (Systemic Lupus), Sjogren's Syndrome | P1 | Unknown | 24 | Open-label | CD19 targeted CAR-T cells |
| NCT07181720 CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors | Renal Cell Carcinoma (RCC), Lung Cancer | P1 | SUSPENDED | 90 | Open-label | CD70-targeted CAR-T cells, CD70-targeted CAR-T cells, CD70-targeted CAR-T cells |
| NCT05415475 Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors | Colorectal Cancer, Esophageal Cancer | P1 | Completed | 30 | Open-label | CEA CAR-T cells |
| NCT05420493 Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma | Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma | P1 | Unknown | 54 | Open-label | CAR-T cells |
| NCT06010862 Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors | Gastric Cancer, Colon Cancer | P1 | Unknown | 36 | Open-label | CEA CAR-T cells, CEA CAR-T cells |
| NCT03029273 NY-ESO-1 TCR （TAEST16001）for Patients With Advanced NSCLC | Lung Cancer, Nonsmall Cell, Recurrent | P1 | Unknown | 20 | Open-label | Cyclophosphamide and Fludarabine, Anti-NY-ESO-1 TCR transduced T cells |
| NCT05420519 Clinical Study of CD70-targeted CAR-T Therapy for Advanced/Advanced Renal Cancer | Metastatic Tumor, Renal Cell Carcinoma | P1 | Unknown | 24 | Open-label | CD70 CAR-T cells |
| NCT03462316 NY-ESO-1-specific T Cell Receptor (TCR) T Cell in Sarcoma | Bone Sarcoma, Soft Tissue Sarcoma | P1 | Completed | 2 | Open-label | NY-ESO-1（TCR Affinity Enhancing Specific T cell Therapy） |
| NCT03159585 To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors | Liver Cancer Stage IV, Gastric Cancer Stage IV | P1 | Completed | 6 | Open-label | TAEST16001 |
| NCT07254208 A Long-term Observational Study in Participants Who Have Received PBGENE-HBV | Chronic HBV Infection | By Invite | 45 | — | PBGENE-HBV | |
| NCT02773940 ClariCore™ Biopsy System in Patients Undergoing Radical Retropubic Prostatectomy | Prostate Cancer | N/A | Unknown | 100 | Open-label | — |
| NCT05848856 The RISC Registry--Risk Informed Screening Registry | Breast Cancer Risk, Cardiovascular Disease Risk | Not Yet Recruiting | 10,000 | — | — | |
| NCT03123757 Assessing the Determinants of 6-minute Walk Test and Its Correlation With Quality of Life | Aged | N/A | Completed | 207 | Open-label | — |
| NCT05461196 Decreasing Opioid Misuse and Habit-forming Behaviors Following Prescription in Patients Undergoing Cesarean Section | Opioid Misuse | N/A | Completed | 100 | RCT, Open-label | — |
| NCT05318625 A Prospective Study to Evaluate the Clinical Performance and Safety of the SIRIUS Endoscope System in Laparoscopic Gynecological Surgery. | Ovarian Cancer, Cervical Cancer | N/A | Unknown | 30 | Open-label | — |
| NCT07696481 Clinical Study on the Safety and Efficacy of PID23 Injection in Patients With Relapsed/Refractory Acute Leukemia | Relapsed or Refractory Acute Leukemia, Relapsed or Refractory Acute Lymphoblastic Leukemia | Early P1 | Not Yet Recruiting | 18 | Open-label | PID23 Injection |
| NCT05585021 Clinical Study on the Effect of Probiotic Compound Powder on the Immunity Improvement of Preschool Children | Immunity | N/A | Completed | 140 | RCT, Single-blind | — |
| NCT07844759 SOLIS: Single-Dose Radiotherapy With Omission of Lumpectomy for Intact Small Breast Cancers | Breast Cancer, Early-Stage Breast Carcinoma | N/A | Not Yet Recruiting | 30 | Open-label | Endocrine Therapy |
| NCT07752862 Prospective Collection and Registry Study of Multicenter, Multidisciplinary Surgical Minimally Invasive Videos | Surgical Neoplasms, Abdominal Surgical Diseases | Not Yet Recruiting | 2,000 | — | — | |
| NCT00767104 Efficacy of Silk - Like Bedding Fabric Pillow Case in the Treatment of Acne Vulgaris | Acne Vulgaris | N/A | Completed | 40 | RCT, Single-blind | — |
| NCT03340142 VIVO™ Accuracy Study | Premature Ventricular Contraction, Ventricular Tachycardia | N/A | Completed | 45 | Open-label | — |
| NCT03504761 ClariCore System Used in Transrectal Ultrasound Guided Prostate Biopsy for Real-Time Tissue Evaluation | Cellular Diagnosis, Prostate Cancer | N/A | Unknown | 325 | Open-label | — |
| NCT04493307 The Evaluation of Hemostasis in Hospitalized COVID-19 Patients | COVID-19 | Unknown | 100 | — | — | |
| NCT04230642 Multicenter Study to Evaluate a New Robotic Device for Image-guided Percutaneous Needle Placement | Hepatic Tumor | N/A | Completed | 22 | Open-label | — |
| NCT05407727 A Prospective, Remote Observational Study in Pediatric Participants With Early-Onset SCN2A-Developmental and Epileptic Encephalopathy | SCN2A-DEE, Epilepsy | Completed | 5 | — | — | |
| NCT06745258 ICARE-LCS QUERI Partnered Evaluation Initiative: Integrating Comprehensive Tobacco Treatment to Enhance Lung Cancer Screening | Tobacco Dependence Treatment, Lung Cancer Screening | Not Yet Recruiting | 7 | — | — | |
| NCT05756712 The Efficacy of White Kidney Bean on Oral Glucose Tolerance Test | Diabetes, Sugar; Blood, High | N/A | Completed | 34 | RCT, Double-blind | — |
| NCT03158571 Chilean Gastric Cancer Task Force (FORCE 1) | Biomarkers | Completed | 116 | — | — | |
| NCT07637929 Non-Interventional Study of Puzol-cel for CD19-Positive Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia | Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (r/r B-ALL) | Not Yet Recruiting | 200 | — | Puzolcabtagene Autoleucel Injection | |
| NCT01355666 Silk-Like Fabric for the Prevention of Pressure Sores in a Long Term Care Setting | Pressure Ulcers | N/A | Unknown | 75 | RCT, Open-label | — |
| NCT06063174 Stress & Resilience Study | Stress, Stress, Psychological | N/A | Completed | 712 | RCT, Open-label | — |
| NCT03707431 Internet Based Cognitive Behavioral Therapy in Pediatric Chronic Pancreatitis | Chronic Pancreatitis, Acute Recurrent Pancreatitis | N/A | Completed | 90 | RCT, Double-blind | — |
| NCT02925741 Silk-Like Bed Linens for Prevention of Unit-Acquired Ulcers | Pressure Ulcer | N/A | Completed | 3,343 | RCT, Open-label | — |
| NCT04305093 Data Mining: Precision Analytical Retrospective Data Correlation | Obesity; Endocrine, Hormone Disturbance | Completed | 144,561 | — | — | |
| NCT04843332 Community Health Workers and Precision Medicine | Cancer, Tumor | N/A | Completed | 110 | RCT, Double-blind | — |
| NCT06030999 The Prevention And Treatment On Obesity And Weight Management By Oral Supplementation Of Probiotics And Prebiotics | Overweight and Obesity | N/A | Completed | 150 | RCT, Double-blind | — |
| NCT05900752 A Multi-Strain Probiotic Reduces the Frequency of Diarrhea in IBS-D Patients | IBS - Irritable Bowel Syndrome, Diarrhea | N/A | Completed | 140 | RCT, Double-blind | — |
| NCT02514590 Wireless Spinal Cord Stimulation for Chronic Pain | Back Pain | N/A | Completed | 49 | Open-label | — |
| NCT01403272 Evaluate the Efficacy of a Silk-Like Fabric for the Prevention of Pressure Sores in a Long Term Care Setting | Pressure Ulcers | N/A | Completed | 75 | RCT, Open-label | — |
| NCT03734575 ClariCore System Used in Transperineal Prostate Biopsy | Prostate Cancer | N/A | SUSPENDED | 60 | Open-label | — |
| NCT02672228 Feasibility of the Vapor Nanobubble Technology for Malaria Diagnostics (MalariaSense) | Malaria | N/A | Completed | 208 | Open-label | — |
| NCT01048814 Retrospective Case Study to Validate Existing Chemoresponse Marker Test in Ovarian, Peritoneal or Fallopian Cancer Cases | Ovarian Cancer, Peritoneal Cancer | Completed | 512 | — | — | |
| NCT01271959 A Study of ChemoFx® Chemoresponse Assay in Solid Tumors - ChemoFx® Registry Study | Solid Organ Tumors | Terminated | 167 | — | — | |
| NCT02910037 Precision Diagnosis of Acute Infectious Diseases; Neuroinflammatory Cohort | Encephalitis, Meningitis | N/A | Completed | 214 | Open-label | — |
| NCT04256395 Efficacy of a Self-test and Self-alert Mobile Applet in Detecting Susceptible Infection of COVID-19 | Susceptibility to Viral and Mycobacterial Infection | Completed | 102,456 | — | — | |
| NCT05682092 Study of Collagen Efficacy on Skin Anti-aging in 30 to 50-Year-Old Women | Skin Laxity, Skin Fold | N/A | Completed | 70 | RCT, Double-blind | — |
| NCT05351060 Novel Splinting Technique Using 3D Models | Arthritis, Osteoarthritis Hand | N/A | Unknown | 10 | Open-label | — |
| NCT06376682 EPIBONE Study: a Prospective Study on Feasibility, Safety and Accuracy | Bone Metastases, Fractures, Bone | N/A | Completed | 34 | Open-label | — |
| NCT03064360 Early Prediction of Major Adverse Cardiovascular Events Using Remote Monitoring | Ischemic Heart Disease | Completed | 200 | — | — | |
| NCT00669422 ChemoFx® PRO - A Post-Market Data Collection Study | Ovarian Cancer, Fallopian Tube Cancer | Terminated | 2,756 | — | — | |
| NCT07856121 The Precision Mito- Mito Map COMPASS Study | Mitochondrial Diseases, Myalgic Encephalomyelitis Chronic Fatigue Syndrome | Not Yet Recruiting | 400 | — | — | |
| NCT04561453 Feasibility Study of Multi-Platform Profiling of Resected Biliary Tract Cancer | Biliary Tract Cancer, Cholangiocarcinoma | Terminated | 14 | — | — | |
| NCT00288275 Correlation of the Chemoresponse Assay With PFS in Patients With Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer | Ovarian Cancer, Fallopian Tube Cancer | Terminated | 256 | — | — | |
| NCT05531981 Detection of Minimal Residual Disease Based on HPV ctDNA in Cervical Cancer | Uterine Cervical Neoplasms | Unknown | 350 | — | — | |
| NCT05717491 Study of Diabetes' Risk Factors and Accelerated Aging According to Socio-economic Status in a Population From the North of France | Diabetes, PreDiabetes | Completed | 2,014 | — | — | |
| NCT01450553 Tissue Collection Study for Patients With Non-Small Cell Lung Cancer With Resectable Disease | Non-Small Cell Lung Cancer | Unknown | 450 | — | — | |
| NCT04815681 Evaluating an Online Wellness Intervention for Greek Adolescents | Depressive Symptoms, Anxiety | N/A | Withdrawn | — | RCT, Double-blind | — |
| NCT06362421 Saliva Testing for High-Risk Human Papillomavirus Infection Oral Cavity and Pharynx Cancer | Oropharyngeal Squamous Cell Carcinoma, Human Papillomavirus Infection | Withdrawn | — | — | — | |
| NCT05710055 The Efficacy on Overweight With Oral Supplemenation of Probiotics and Prebiotics | Overweight | N/A | Completed | 200 | RCT, Double-blind | — |
| NCT05651867 EPIONE Guided Lung Evaluation | Lung Cancer | N/A | Completed | 25 | Open-label | — |
| NCT01007890 Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer | Breast Cancer | Terminated | 134 | — | — | |
| NCT03349918 PERsonal ContExtual Precision healTh | Hypertension, Depression | N/A | Completed | 164 | Open-label | — |
| NCT05529979 Epione® Post-Market Clinical Follow-up Study | Cancer Abdomen | Completed | 55 | — | — | |
| NCT04639739 Anti-CD19 CAR NK Cell Therapy for R/R Non-Hodgkin Lymphoma. | NHL | Early P1 | Unknown | 9 | Open-label | anti-CD19 CAR NK |
| NCT05517889 Repeatability and Stability of Healthy Skin Features on OCT | Optical Coherence Tomography, Artificial Intelligence | Completed | 20 | — | — | |
| NCT05048407 Sirius in Gynaecological Laparoscopic Surgery | Ovarian Cancer, Cervical Cancer | N/A | Unknown | 30 | Open-label | — |
| NCT01049126 Retrospective Case Study Examining Patient Outcomes Compared to the ChemoFx Assay in Endometrial Cancer Patients | Endometrial Cancer | Completed | 76 | — | — | |
| NCT03091101 Impact of Scleral Contact Lens Wear on Corneal Nerves in Keratoconus | Keratoconus | N/A | Completed | 8 | Open-label | — |
| NCT04990089 VIVO European Observational Registry | Ventricular Arrythmia, Ventricular Tachycardia | Completed | 125 | — | — | |
| NCT02928640 ClariCore Optical Biopsy System Used in TRUS (Trans-Rectal Ultrasound)-Guided Prostrate Biopsy | Cellular Diagnosis, Prostate Cancer | N/A | Unknown | 200 | Open-label | — |
| NCT05696938 Improved Skin Whitening Outcomes Associated With Nicotinamide Fortified Consumption in 30 to 50- Year-old Women | Skin Darken | N/A | Completed | 70 | RCT, Double-blind | — |
| NCT00705185 Exploring a Potential Blood Test to Diagnose Major Depressive Disorder | Major Depressive Disorder | Completed | 120 | — | — |